+39 02 610346.1 - info@newron.com

Latest press releases

  • 15Jan
    Newron initiates Phase II study of sNN0029 in patients with Amyotrophic Lateral Sclerosis

     

  • 15Jan
    Newron announces results of Phase I study of NW-3509; Phase II study in schizophrenia patients planned for Q2 2015

     

  • 14Jan
    Newron initiates Phase II study of sNN0031 in patients with Parkinson’s disease

     

  • 29Dec
    Safinamide New Drug Application (NDA) Re-submitted to the US Food and Drug Administration (FDA)

     

  • 19Dec
    CHMP recommends Approval of XadagoTM (safinamide) to treat Parkinson´s disease in the EU

     

  • 19Dec
    CHMP recommendation on safinamide to treat Parkinson´s disease in the EU expected today.

View All

Newron share price

Events

  • 11Feb
    Leerink Global Healthcare Conference

    February 11-12, 2015  - The Waldorf Astoria, New York City, US

  • 9Feb
    17th Annual BIO CEO & Investor Conference

    February 9-10, 2015  - The Waldorf Astoria, New York City, US

  • 12Jan
    33rd Annual J.P. Morgan Healthcare Conference

    January 12-15, 2015 - the Westin St. Francis, San Francisco, US

View Event Calendar